Verrica Pharmaceuticals Inc. (VRCA) — 10-Q Filings
All 10-Q filings from Verrica Pharmaceuticals Inc.. Browse 6 Quarterly Report reports with AI-powered summaries and risk analysis.
10-Q Filings (6)
-
Verrica Slashes Losses 84% on Revenue Surge, But Going Concern Looms
— Nov 14, 2025 Risk: high
Verrica Pharmaceuticals Inc. reported a significant turnaround in its financial performance for the nine months ended September 30, 2025, reducing its net loss -
Verrica's YCANTH Drives Revenue Growth, Narrows Q2 Loss
— Aug 12, 2025 Risk: medium
Verrica Pharmaceuticals Inc. reported product revenue of $1.5 million for the three months ended June 30, 2025, and $2.8 million for the six months ended June 3 -
Verrica Pharma Files Q1 2025 10-Q, Details Torii Deal & Financing
— May 13, 2025 Risk: medium
Verrica Pharmaceuticals Inc. filed its 10-Q for the period ending March 31, 2025. The filing details financial performance and operational updates, including re -
Verrica Pharmaceuticals Files Q3 2024 10-Q
— Nov 5, 2024 Risk: medium
Verrica Pharmaceuticals Inc. filed its Q3 10-Q report for the period ending September 30, 2024. The company's financial statements and disclosures are presented -
Verrica Pharmaceuticals Files Q2 2024 10-Q
— Aug 14, 2024 Risk: medium
Verrica Pharmaceuticals Inc. filed its 10-Q for the period ending June 30, 2024. The filing details financial activities and operational updates, including info -
Verrica Pharmaceuticals Inc. Files 10-Q for Period Ending March 31, 2024
— May 13, 2024 Risk: medium
Verrica Pharmaceuticals Inc. (VRCA) filed a Quarterly Report (10-Q) with the SEC on May 13, 2024. Verrica Pharmaceuticals Inc. filed a 10-Q report for the perio
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX